Podcast on Procrit, NY Times Story and Anemia Drugs

In a front page story today the New York Times exposed a little known, but long practiced, policy by which anemia drugs are marketed to doctors, oncologists and other medical professionals through a series of payments, sales incentives and other inducements.

You can read the entire NY Times article by clicking this link.

As you know the Civil Action Center and LBN have been following this story closely for the last 2 months and will continue to report on these developments, particularly with the long awaited hearing tomorrow at the FDA on the safety issues surrounding this particular class of drugs who are marketed under names such as Procit, Epogen and Aranesp. The two major manufacturers of these drugs are Johnson & Johnson through their Ortho subsidiary and by Amgen.

Today Attorney Jan Schlichtmann had as his guest on Civil Action Radio nationally renown trial lawyer Roberta Ashkin of New York, NY., discussing the NY Times article, the marketing abuses and also the ESA trust which has been formed to begin the process of discovering what injuries might have occurred due to the over use of this class of injectable anemia treatments.

You can listen to the entire podcast by clicking here.

This is going to be a major and continuing story so subscribe to our RSS feed or podcasts to stay abreast of this information.